KPV

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), a peptide hormone derived from proopiomelanocortin (POMC). While α-MSH itself is an endogenous 13-amino-acid peptide with well-characterized roles in pigmentation, inflammation, and energy homeostasis, research has identified the C-terminal KPV sequence as the minimal fragment responsible for α-MSH's anti-inflammatory activity. This specificity has made KPV a useful research tool for studying melanocortin anti-inflammatory pathways independently of pigmentation effects.

The most extensively studied application of KPV is in models of intestinal inflammation. Research groups, particularly those studying inflammatory bowel disease (IBD) models, have documented KPV's ability to protect colonic epithelium and reduce inflammatory parameters in murine colitis models including DSS-induced and TNBS-induced colitis. Studies have shown that KPV reduces neutrophil infiltration, decreases production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β), and attenuates activation of NF-κB — a central transcription factor in inflammatory signaling.

A notable pharmacokinetic advantage of KPV for gut research is its stability in the gastrointestinal environment and its apparent ability to be absorbed intact through intestinal epithelial cells in some experimental systems. Research has demonstrated that KPV exerts direct anti-inflammatory effects on intestinal epithelial cells in addition to systemic effects, making it relevant to local mucosal biology studies.

KPV is available for laboratory and research use only. Investigators in immunology, gastroenterology research, and melanocortin biology will find extensive primary literature on KPV's receptor interactions and therapeutic potential in inflammatory models.